El Sahly HM, Atmar RL. An Early Look at mRNA Vaccines to Prevent Influenza. N Engl J Med. 2025 Nov 20;393(20):2048-2050
Annual influenza vaccination campaigns are a trusted tool in efforts to decrease the morbidity and mortality of influenza in the United States, with an effectiveness of 36 to 54% at preventing influenza-related outpatient medical visits and 41 to 55% at preventing influenza-related hospitalizations in adults during the most recent 2024-2025 season.1 Short of developing a universal influenza vaccine with effectiveness that spans multiple seasons and influenza subtypes, the development of seasonal influenza vaccines with improved effectiveness would constitute an important public health advance. Vaccine developers have leveraged the recent successes of the messenger RNA (mRNA) vaccine platform against Covid-19 and
See Also:
Latest articles in those days:
- The evolution and transmission dynamics of H3N2 influenza virus identified in a respiratory disease outbreak in companion dogs in Alabama, USA 5 hours ago
- Structural and functional characterization of hemagglutinin E190D and Q226H minor variants in human H5N1 A/British Columbia/PHL-2032/2024 5 hours ago
- Spatial risk factors associated with outbreaks of highly pathogenic avian influenza in Pennsylvania’s commercial poultry farms 6 hours ago
- [preprint]H9N2 avian influenza virus in Bangladesh: three genetically distinct co-circulating subgroups retain a largely conserved antigenic phenotype 6 hours ago
- [preprint]Endogenous serine proteases in MDCK sublines support trypsin-independent influenza A virus replication 6 hours ago
[Go Top] [Close Window]


